Encompass Health
EHC
$99.84
-3.23%
Encompass Health Corporation is a leading provider of post-acute healthcare services in the United States, operating a national network of inpatient rehabilitation hospitals. The company is a pure-play market leader in the inpatient rehabilitation facility (IRF) segment, specializing in rehabilitative care for patients recovering from strokes, neurological disorders, cardiac conditions, and complex orthopedic injuries. The current investor narrative centers on the company's ability to navigate a challenging operating environment marked by labor cost pressures and reimbursement dynamics, while its consistent dividend declarations, as highlighted in recent news, underscore its financial stability and commitment to returning capital to shareholders.…
EHC
Encompass Health
$99.84
Related headlines
Investment Opinion: Should I buy EHC Today?
Rating & Thesis: Hold. EHC presents a classic 'value trap' scenario—it appears cheap on historical P/E and cash flow metrics, but faces clear and significant operational headwinds that justify its depressed price and negative momentum. The limited analyst community maintains a positive long-term outlook (Overweight/Buy ratings), but the market is rightly focused on near-term margin pressures.
Supporting Evidence: The stock trades at a forward P/E of 16.27x, which is a discount to its trailing multiple of 18.84x and sits at the lower end of its two-year historical P/E range (15x-25x). It generates substantial free cash flow ($439.2M TTM) supporting its dividend (0.67% yield). Profitability metrics like a 9.54% net margin and 23.22% ROE remain solid. However, these positives are counterbalanced by the severe technical downtrend, margin compression, and revenue growth deceleration.
Risks & Conditions: The two biggest risks are 1) sustained gross margin pressure eroding earnings, and 2) continued negative price momentum breaking key support. This Hold would upgrade to a Buy if the company demonstrates a clear rebound in gross margins above 30% in the next quarter or if the stock stabilizes above $110 with improving volume. It would downgrade to a Sell if Q4 margin compression is confirmed as a new trend in subsequent earnings or if the stock breaks below $92.77 support. The stock is fairly valued relative to its own challenged near-term prospects but undervalued if operational issues prove transient.
Sign up to view all
EHC 12-Month Price Forecast
The investment thesis for EHC hinges almost entirely on the resolution of the gross margin question. The company's fundamentals are bifurcated: exceptionally strong cash flow and returns versus a potentially deteriorating cost structure. The low valuation and high cash flow provide a margin of safety, but the negative price momentum and lack of a near-term catalyst suggest the stock is likely to remain range-bound or drift lower until operational clarity emerges. The stance is neutral with medium confidence because the next 1-2 earnings reports are critical. An upgrade to bullish would require clear evidence of margin recovery; a downgrade to bearish would be triggered by confirmation of sustained compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Encompass Health's 12-month outlook, with a consensus price target around $129.79 and implied upside of +30.0% versus the current price.
Average Target
$129.79
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$80 - $130
Analyst target range
Analyst coverage for EHC appears limited, with only two analysts providing estimates for future EPS and revenue, and no consensus price target or recommendation data provided in the key inputs. This indicates insufficient analyst coverage to form a reliable consensus view, which is typical for some mid-cap stocks and can lead to higher volatility and less efficient price discovery as the stock is less scrutinized by institutional research. The available institutional ratings from the past year show a pattern of reiterated bullish stances, with firms like Barclays, UBS, and B of A Securities maintaining 'Overweight' or 'Buy' ratings, suggesting that the limited analyst community following the stock maintains a positive long-term outlook despite recent price weakness.
Bulls vs Bears: EHC Investment Factors
The bear case currently holds stronger evidence, primarily driven by the stock's persistent technical weakness and the alarming single-quarter gross margin compression. The most important tension in the investment debate is whether the Q4 gross margin drop is a one-time anomaly or the start of a sustained profitability squeeze. If it's the latter, the company's ability to maintain its dividend and growth investments despite rising labor costs is severely challenged. The bull case rests on the stock's valuation being at a historical discount and its strong underlying cash generation, but these factors have so far failed to attract buyers in the face of operational concerns.
Bullish
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $439.2 million. This provides significant financial flexibility to fund its consistent dividend (recently declared), share repurchases, and growth investments without straining the balance sheet.
- Healthy Profitability and Return Metrics: EHC maintains solid profitability with a trailing net margin of 9.54% and a high Return on Equity (ROE) of 23.22%. This demonstrates efficient capital allocation and an ability to generate strong returns for shareholders despite sector headwinds.
- Valuation at Lower End of Historical Range: The stock's trailing P/E of 18.84x is below its recent historical range (15x-25x), suggesting a potential value opportunity. The forward P/E of 16.27x implies a modest discount for anticipated earnings growth.
- Defensive Business Model with Low Beta: EHC's business is non-cyclical, providing essential post-acute care. This is reflected in a beta of 0.576, indicating low volatility relative to the market. This defensive profile can be attractive during economic uncertainty.
Bearish
- Sustained Technical Downtrend: The stock is in a clear downtrend, down 12.22% over the past year and trading near the lower 37% of its 52-week range ($92.77 - $127.99). It has shown severe negative relative strength of -36.53% vs. the S&P 500, indicating persistent selling pressure and weak investor sentiment.
- Sharp Gross Margin Compression: The Q4 2025 gross margin of 22.78% is a significant and alarming drop from the trailing figure of 95.71% (though the latter may be anomalous). This quarter's margin suggests severe cost pressure, likely from labor inflation, which directly threatens profitability.
- Revenue Growth Deceleration: While Q4 revenue grew 9.94% YoY, this represents a slowdown from the stronger sequential growth in prior 2025 quarters. This normalization post-pandemic recovery raises questions about the sustainability of top-line momentum in a challenging operating environment.
- Moderate Financial Leverage: The company carries a Debt-to-Equity ratio of 1.11. While manageable, this leverage could become a headwind if rising interest rates increase borrowing costs or if operating margins continue to compress, putting pressure on interest coverage.
EHC Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of -12.22% and a current price of $106.10, which positions it at approximately 37% of its 52-week range ($92.77 to $127.99), indicating it is trading much closer to its yearly lows than highs and suggesting a lack of momentum and potential oversold conditions. Recent momentum shows a slight divergence, with the stock down 0.27% over the past month and down 3.14% over the past three months, which, while negative, is less severe than the full-year decline and could hint at a potential deceleration in selling pressure or a basing pattern. Key technical levels are clearly defined, with immediate support at the 52-week low of $92.77 and resistance at the 52-week high of $127.99; a breakdown below $92.77 would signal a new leg down, while a sustained move above the recent high near $116.25 is needed to suggest a trend reversal. The stock's beta of 0.576 indicates it is approximately 42% less volatile than the broader market (SPY), which has gained 24.31% over the past year, highlighting EHC's significant negative relative strength of -36.53% and its defensive, low-volatility characteristics that have failed to provide downside protection in this instance.
Beta
0.58
0.58x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$93-$128
Price range past year
Annual Return
-17.7%
Cumulative gain past year
| Period | EHC Return | S&P 500 |
|---|---|---|
| 1m | -5.1% | +4.6% |
| 3m | -6.6% | +12.6% |
| 6m | -11.3% | +10.4% |
| 1y | -17.7% | +27.0% |
| ytd | -6.1% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EHC Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration; the most recent Q4 2025 revenue was $1.5446 billion, representing a 9.94% year-over-year increase, yet this growth rate has moderated from the stronger sequential performances seen in prior quarters of 2025, indicating a potential normalization in demand following post-pandemic recovery. Profitability is solid, with the company reporting net income of $146.1 million in Q4 2025 and a trailing net margin of 9.54%, though the quarterly gross margin of 22.78% is notably lower than the trailing gross margin figure of 95.71% (which appears to be an anomaly in the data), suggesting potential reporting differences or one-time impacts that warrant closer scrutiny against industry norms for inpatient rehab. The balance sheet and cash flow position is healthy, with a debt-to-equity ratio of 1.11 indicating moderate leverage, a current ratio of 1.08 showing adequate short-term liquidity, and strong free cash flow generation evidenced by a trailing twelve-month FCF of $439.2 million, which provides ample internal funding for dividends, share repurchases, and growth investments.
Quarterly Revenue
$1.5B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.22%
Latest Quarter
Free Cash Flow
$439199999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EHC Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 18.84x and a forward PE of 16.27x; the lower forward multiple suggests the market anticipates modest earnings growth, though the discount is not particularly wide. Peer comparison data is not available in the provided dataset, preventing a direct assessment of whether EHC trades at a premium or discount to its industry peers in the Medical Care Facilities sector. Historically, the current trailing PE of 18.84x sits below the stock's own recent historical range observed over the past two years, where quarterly PE ratios have fluctuated between approximately 15x and 25x, suggesting the stock is not at historical highs and may offer a relative value opportunity if the fundamental outlook stabilizes.
PE
18.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 14x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the sharp contraction in gross margin to 22.78% in Q4 2025 from much higher levels in prior periods. This indicates significant pressure from labor and other input costs, which could compress the healthy 9.54% net margin if not managed. Revenue growth deceleration to 9.94% YoY also poses a risk to the valuation, which relies on stable growth. Furthermore, the debt-to-equity ratio of 1.11, while moderate, adds financial risk in a rising interest rate environment, potentially increasing interest expense on its $30.2 million quarterly burden.
Market & Competitive Risks: The stock's significant underperformance (-12.22% vs. SPY +24.31% over one year) highlights severe negative market sentiment and a lack of catalysts. Trading near the bottom of its 52-week range suggests the market is pricing in continued operational headwinds. The low beta of 0.576, while defensive, has not provided downside protection, indicating company-specific issues outweigh its non-cyclical nature. Competitive and regulatory risks in the healthcare reimbursement landscape could further pressure pricing and volumes.
Worst-Case Scenario: The worst-case scenario involves the Q4 gross margin compression becoming a structural trend due to permanent labor cost inflation and fixed reimbursement rates. This could trigger a downward spiral of earnings misses, dividend sustainability concerns, and multiple compression. Combined with a broader market sell-off, this could push the stock to retest and break its 52-week low of $92.77. A realistic downside from the current price of $106.10 is approximately -12.6% to that level, with further potential decline if sentiment deteriorates further, approaching the -26.22% max drawdown recently observed.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Sustained gross margin compression (Q4 margin fell to 22.78%) from labor inflation threatens the core profitability of the business. 2) Market/Sentiment Risk: The stock is in a severe downtrend with -12.22% 1-year return and -36.53% relative strength vs. the market, indicating poor sentiment and momentum. 3) Financial Risk: A Debt-to-Equity ratio of 1.11 introduces leverage risk in a rising rate environment. 4) Liquidity/Risk: Limited analyst coverage (only 2 analysts) can lead to higher volatility and inefficient price discovery.
Our 12-month outlook presents three scenarios. The Base Case (60% probability) sees the stock trading between $100 and $115 as margin pressures stabilize but growth moderates, leaving the stock range-bound. The Bull Case (25% probability) projects a rally to $120-$128 on a successful margin recovery and renewed investor confidence. The Bear Case (15% probability) warns of a drop to $85-$95 if margin compression is confirmed and the dividend is threatened. The base case is most likely, centered on the assumption that the company manages a slow, grinding recovery without a major catalyst for a re-rating.
EHC appears fairly valued to slightly undervalued based on its own history, but this is justified by its operational challenges. The trailing P/E of 18.84x is below its recent historical range (15x-25x), suggesting a discount. The forward P/E of 16.27x implies the market expects modest earnings growth. However, without peer comparison data, it's difficult to assess relative value. The current valuation implies the market expects continued pressure on profitability and growth deceleration. If the company can stabilize margins, the stock is likely undervalued; if not, it may still be overvalued despite the drop.
EHC is a speculative buy only for patient, value-oriented investors with a high tolerance for risk. At its current price near 52-week lows and a forward P/E of 16.27x, it offers a valuation discount and a 0.67% dividend supported by strong free cash flow. However, it is not a good buy for most investors due to the severe gross margin compression revealed in Q4 2025 and the persistent negative price momentum. The stock could be a good buy if the margin issue proves temporary, but it carries significant downside risk if not. It is best suited for contrarians willing to bet on an operational turnaround.
EHC is unsuitable for short-term trading due to its low beta (0.576), negative momentum, and lack of near-term catalysts. It is primarily a long-term, turnaround investment for investors with a 2-3 year horizon. This timeframe allows for the operational issues (margin pressure) to be resolved and for the company's strong free cash flow generation to potentially drive shareholder returns via dividends and buybacks. The low volatility is a benefit for long-term holders but a detriment for traders seeking momentum. Given the current uncertainties, a minimum holding period of 12-18 months is suggested to assess the durability of the recovery.